10 x Mazdutide 10mg

For research purposes only, this product is not intended for human consumption, diagnosis, or treatment. It has not been approved by the FDA or MHRA. Sales are limited to qualified researchers and institutions, and misuse could lead to account termination or legal consequences.

Mazdutide is a first-in-class synthetic peptide that acts as a dual agonist for GLP-1 and glucagon receptors, supporting significant weight loss and glycemic control through appetite suppression and increased energy expenditure.

Mazdutide mimics the natural gut hormone oxyntomodulin (OXM) and activates two key receptors:
GLP-1 receptors (GLP-1R): Found in the pancreas, brain, and digestive system, activation promotes insulin secretion, delays gastric emptying, suppresses appetite, and regulates postprandial blood sugar levels

Glucagon receptors (GCGR): Located in the liver and brown adipose tissue, activation increases energy expenditure, lipolysis, and thermogenesis, contributing to fat loss without causing hyperglycemia due to the compensatory GLP-1 activity

This dual-receptor activity differentiates mazdutide from GLP-1-only agonists like semaglutide and dual incretin agonists like tirzepatide, as it combines satiety regulation with increased metabolic output

Clinical Applications and Efficacy
Mazdutide is primarily investigated for:
Chronic weight management: Phase 3 trials (GLORY-1 and GLORY-2) in overweight or obese adults reported 11–14% weight loss at 48 weeks at 4–6mg weekly doses, with some participants achieving reductions of ≥15%

The drug also reduced waist, hip, and neck circumferences and decreased liver fat content, benefiting metabolic health

Type 2 Diabetes (T2D): Mazdutide enhances insulin secretion, lowers HbA1c, and improves lipid profiles. For example, in adults with T2D, the 6mg weekly dose yielded HbA1c reductions up to -2.15% and weight loss of -9.6% at 24 weeks